Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma.

Abstract

Few safe and effective treatments are available for melasma. Cysteamine, a non-melanocytotoxic molecule is a safer alternative to hydroquinone and usable for long-term use. To evaluate the effect of cysteamine 5% cream in the treatment of melasma. Sixty-five of 80 patients completed this single-blind, randomized, controlled trial. The patients received cysteamine 5% or hydroquinone 4%/ascorbic acid 3% (HC) cream. The therapeutic response was evaluated by modified MASI (mMASI) and melanin index (SkinColorCatch) after 2 and 4months of treatment. The effect of treatment on the quality of life was also assessed. The decrease in mMASI score was from 6.69±2.96 to 4.47±2.16 in the cysteamine group and from 6.26±3.25 to 3.87±2.00 in the HC group after 4months (p values<0.001). The melanin index decreased from 37.72±10.17 to 31.47±11.90 in the cysteamine group and from 36.37±10.80 to 23.16±8.83 in the HC group after 4months (p-value=0.003 and <0.001, respectively). The difference between mMASI score at baseline and month 4 was not significant between both groups (p-value>0.05). The difference between the melanin index at baseline and month 4 was significantly more pronounced in the HC group (p-value=0.002). Quality of life improved in both groups (p-value<0.05), but was not significantly different between groups (p-value>0.05). Cysteamine was confirmed to be an effective treatment for melasma, with equivalent results to HC in reducing mMASI score and improving quality of life, despite lesser melanin index reduction observed. Cysteamine and HC efficacy was confirmed in patients recalcitrant to previous treatments, by a significant reduction of mMASI and melanin index.